netilmicin and Brucellosis

netilmicin has been researched along with Brucellosis* in 2 studies

Other Studies

2 other study(ies) available for netilmicin and Brucellosis

ArticleYear
Brucella isolated from bone marrow.
    The Journal of the Association of Physicians of India, 2003, Volume: 51

    A 40 year patient presented with pyrexia of one month duration. Routine work up for fever of unknown origin (FUO) was negative. Bone marrow aspiration and culture done yielded Brucella. Bone marrow cultures are recommended for patients for FUO for whom the routine workup turns out to be negative. Serological tests for brucellosis can be false-negative in some cases of brucellosis due to prozone phenomena.

    Topics: Adult; Anti-Bacterial Agents; Bone Marrow; Brucella; Brucellosis; Doxycycline; Drug Therapy, Combination; Enzyme Inhibitors; Humans; India; Male; Netilmicin; Rifampin

2003
Treatment of human brucellosis with netilmicin and doxycycline.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1996, Volume: 22, Issue:3

    We conducted a prospective, noncomparative, multicenter study to assess the safety and efficacy of doxycycline and netilmicin in the treatment of human brucellosis. The study included 64 patients who had acute brucellosis without endocarditis or neurobrucellosis. The treatment schedule consisted of the administration of 100 mg of doxycycline (or 5 mg/[kg.d] if body weight < or = 40 kg) twice a day orally for 45 days, plus 300 mg of netilmicin (6 mg/[kg.d] if body weight < or = 50 kg) intramuscularly once daily for 7 days. Therapeutic failure was noted in 5 patients (7.7%; 95% confidence interval [CI], 2.5%-17.1%), of whom 2 had spondylitis, 1 had sacroiliitis, and 1 had a splenic abscess that required splenectomy. Relapse was noted in eight patients (12.5%; 95% CI, 5.6%-23.2%). When relapse was considered in combination with initial lack of efficacy, 13 patients (21.9%; 95% CI, 12.3%-33.9%) failed to respond to therapy. Fifteen patients (23%; 95% CI, 13.5%-35.2%) had adverse effects, and one patient (1.5%) had a treatment-limiting adverse effect. Combination therapy with netilmicin/doxycycline may be effective in treating acute brucellosis. However, prospective controlled trials must confirm these results.

    Topics: Acute Disease; Adolescent; Adult; Aged; Brucellosis; Child; Doxycycline; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Netilmicin; Prospective Studies; Recurrence; Treatment Outcome

1996